Open AccessKinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial
Author(s) -
Stéphanie Dulucq,
Franck E. Nicolini,
Delphine Réa,
Pascale ConyMakhoul,
Aude Charbonnier,
Martine EscoffreBarbe,
Valérie Coiteux,
Pascal Lenain,
Françoise RigalHuguet,
Jixing Liu,
Agnès GuerciBresler,
Laurence Legros,
JeanChristophe Ianotto,
Martine Gardembas,
Pascal Turlure,
Viviane Dubruille,
Philippe Rousselot,
Juliana Martiniuc,
Henry Jardel,
Hyacinthe JohnsonAnsah,
Bertrand Joly,
T Henni,
Émilie Cayssials,
Patricia Zunic,
Marc Berger,
Bruno Villemagne,
Fanny Robbesyn,
Stéphane Morisset,
FrançoisXavier Mahon,
Gabriel Étienne
Publication year - 2022
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2022.280811
Subject(s) - discontinuation , imatinib , medicine , myeloid leukemia , clinical trial , tyrosine kinase , oncology , receptor